What was the overall market valuation of the heart failure-drugs market in 2024?

The overall market valuation was $876.9 Million in 2024. Read More

What is the projected market valuation for the heart failure-drugs market by 2035?

The projected valuation for 2035 is $1,134.63 Million. Read More

What is the expected CAGR for the heart failure-drugs market during the forecast period 2025 - 2035?

The expected CAGR for the heart failure-drugs market during the forecast period 2025 - 2035 is 2.37%. Read More

Which drug class had the highest valuation in the heart failure-drugs market in 2024?

Diuretics had the highest valuation, ranging from $250.0 Million to $300.0 Million in 2024. Read More

What are the projected valuations for Beta Blockers in the heart failure-drugs market by 2035?

The projected valuations for Beta Blockers are expected to range from $200.0 Million to $250.0 Million by 2035. Read More

How does the valuation of Oral administration route compare to Intravenous in 2024?

In 2024, the valuation for Oral administration was $350.0 Million to $450.0 Million, while Intravenous was $300.0 Million to $400.0 Million. Read More

What was the market valuation for Chronic Heart Failure drugs in 2024?

The market valuation for Chronic Heart Failure drugs was between $450.0 Million and $600.0 Million in 2024. Read More

Which distribution channel had the same valuation range in 2024?

Both Hospital Pharmacy and Retail Pharmacy had the same valuation range of $350.0 Million to $450.0 Million in 2024. Read More

What is the expected growth trend for the heart failure-drugs market in the coming years?

The heart failure-drugs market is likely to experience steady growth, with a projected CAGR of 2.37% from 2025 to 2035. Read More

Who are the key players in the heart failure-drugs market?

Key players in the market include Novartis, Bristol-Myers Squibb, Merck & Co., Amgen, Bayer, Pfizer, Gilead Sciences, AstraZeneca, and Roche. Read More

GCC Heart Failure Drugs Market

ID: MRFR/MED/50692-HCR

200 Pages

Vikita Thakur

Last Updated: April 06, 2026

GCC Heart Failure Drugs Market Research Report: Size, Share, Trend Analysis By Drug Class (Angiotensin-Converting Enzyme Inhibitors, Beta Blockers, Diuretics, Angiotensin II Receptor Blockers, Mineralocorticoid Receptor Antagonists), By Administration Route (Oral, Intravenous, Subcutaneous), By Patient Type (Acute Heart Failure, Chronic Heart Failure, Heart Failure with Preserved Ejection Fraction) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth Outlook & Industry Forecast 2025 To 2035

GCC Heart Failure Drugs Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Drug Class (USD Million)
  1. 4.1.1 Angiotensin-Converting Enzyme Inhibitors
  2. 4.1.2 Beta Blockers
  3. 4.1.3 Diuretics
  4. 4.1.4 Angiotensin II Receptor Blockers
  5. 4.1.5 Mineralocorticoid Receptor Antagonists
2. 4.2 Food, Beverages & Nutrition, BY Administration Route (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Intravenous
  3. 4.2.3 Subcutaneous
3. 4.3 Food, Beverages & Nutrition, BY Patient Type (USD Million)
  1. 4.3.1 Acute Heart Failure
  2. 4.3.2 Chronic Heart Failure
  3. 4.3.3 Heart Failure with Preserved Ejection Fraction
4. 4.4 Food, Beverages & Nutrition, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospital Pharmacy
  2. 4.4.2 Retail Pharmacy
  3. 4.4.3 Online Pharmacy
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck & Co. (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Amgen (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bayer (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Gilead Sciences (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Roche (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GCC MARKET ANALYSIS BY DRUG CLASS
3. 6.3 GCC MARKET ANALYSIS BY ADMINISTRATION ROUTE
4. 6.4 GCC MARKET ANALYSIS BY PATIENT TYPE
5. 6.5 GCC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
12. 6.12 FOOD, BEVERAGES & NUTRITION, BY DRUG CLASS, 2024 (% SHARE)
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY DRUG CLASS, 2024 TO 2035 (USD Million)
14. 6.14 FOOD, BEVERAGES & NUTRITION, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
15. 6.15 FOOD, BEVERAGES & NUTRITION, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
16. 6.16 FOOD, BEVERAGES & NUTRITION, BY PATIENT TYPE, 2024 (% SHARE)
17. 6.17 FOOD, BEVERAGES & NUTRITION, BY PATIENT TYPE, 2024 TO 2035 (USD Million)
18. 6.18 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 GCC MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  2. 7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
  3. 7.2.3 BY PATIENT TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

GCC Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Drug Class (USD Million, 2025-2035)

Angiotensin-Converting Enzyme Inhibitors
Beta Blockers
Diuretics
Angiotensin II Receptor Blockers
Mineralocorticoid Receptor Antagonists

Food, Beverages & Nutrition By Administration Route (USD Million, 2025-2035)

Oral
Intravenous
Subcutaneous

Food, Beverages & Nutrition By Patient Type (USD Million, 2025-2035)

Acute Heart Failure
Chronic Heart Failure
Heart Failure with Preserved Ejection Fraction

Food, Beverages & Nutrition By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”